During its fourth quarter and full-year 2011 earnings call Feb. 24, Idenix reported that it will begin a broad Phase IIb program testing its nucleoside polymerase inhibitor IDX184 in multiple interferon-free combinations of direct-acting antivirals for hepatitis C. The biotech also launched a Phase I safety and pharmacokinetics study of NS5A inhibitor IDX719 earlier this quarter.
Financings of the fortnight sees troubled Alnylam raise an $86 million FOPO, while Adocia completes Europe’s first biopharma IPO this year. Plus news on recent financings by Satori, Ceptaris, Vernalis and Exelixis.
Centers for Medicare & Medicaid Services boosts health information exchange requirements in the meaningful use stage 2 proposed rule.
